PURPOSE Standard adjuvant treatment for stage III colorectal cancer (CRC) combines intravenous oxaliplatin with a fluoropyrimidine, either with intravenous 5-fluorouracil with folinic acid oxaliplatin, capecitabine (CAPOX). This study aims to describe the toxicity of these two regimens in patients with a diverting stoma. METHODS We conducted a retrospective, single-center study of patients with stage III CRC who had a diverting stoma and received adjuvant treatment with either FOLFOX or CAPOX between January 2016 and July 2023. Clinical characteristics and treatment details were extracted from electronic health records. The primary end point was the rate of hospitalization during adjuvant chemotherapy. Secondary end points included treatment compliance and toxicity. RESULTS A total of 87 patients with CRC and a diverting stoma received treatment with either CAPOX (n = 37) or modified FOLFOX regimen: oxaliplatin, 5-fluorouracil, folinic acid (mFOLFOX6) (n = 50). No patient had dihydropyrimidine dehydrogenase deficiency. Baseline clinical characteristics were similar between groups. The hospitalization rate was 35% with CAPOX and 18% with FOLFOX ( P = .07). Most hospitalizations occurred during the first cycles of adjuvant treatment and were primarily related to digestive toxicities. Higher hospitalization rates with CAPOX were observed across all subgroups, regardless of sex, age, performance status, or renal function. CONCLUSION Patients with a diverting stoma who receive adjuvant chemotherapy with fluoropyrimidines and oxaliplatin are at higher risk of severe digestive toxicities when treated with the CAPOX regimen. The mFOLFOX6 regimen appears to be safer alternative in this population.
Marqués et al. (Thu,) studied this question.